William G. Lowrie Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, Ohio, USA.
Biotechnol Prog. 2022 Jan;38(1):e3219. doi: 10.1002/btpr.3219. Epub 2021 Oct 14.
Polymerized hemoglobin (Hb)-based oxygen carriers (HBOCs) are a scalable and cost-effective red blood cell (RBC) substitute. However, previous generations of commercial polymerized HBOCs elicited oxidative tissue injury in vivo due to the presence of low molecular weight polymeric Hb species (<500 kDa) and cell-free Hb (64 kDa). Polymerized human Hb (PolyhHb) locked in the tense quaternary state (T-state) exhibits great promise to meet clinical needs where past polymerized HBOCs failed. This work shows that separation of T-state PolyhHb via a two-stage tangential flow filtration (TFF) purification train such that the Hb polymers are bracketed between 500 kDa and 0.2 μm creates a uniform polymer size and largely eliminates the Hb species which elicit deleterious side effects in vivo. Biophysical characterization of these materials demonstrates their potential effectiveness as an RBC substitute and verifies the low percentage of low molecular weight Hb polymers and cell-free Hb. Size exclusion chromatography confirms that T-state PolyhHb can be consistently produced in a size range between 500 kDa and 0.2 μm. Furthermore, the average molecular weight of all PolyhHb species produced is one or two orders of magnitude larger than that of the commercial polymerized HBOCs Hemolink and Oxyglobin, respectively. Haptoglobin binding kinetics confirms that two-stage TFF processing of PolyhHb reliably removes cell-free Hb and low molecular weight polymeric Hb species. T-state PolyhHbs demonstrate lower auto-oxidation rates compared to unmodified Hb and prior generations of commercial polymerized HBOCs. These results demonstrate T-state PolyhHb's feasibility as a next-generation polymerized HBOC for potential use in transfusion medicine.
聚合血红蛋白(Hb)基氧载体(HBOCs)是一种可扩展且具有成本效益的红细胞(RBC)替代品。然而,由于存在低分子量聚合 Hb 物质(<500 kDa)和无细胞 Hb(64 kDa),前几代商业聚合 HBOCs 在体内引起氧化组织损伤。处于紧张的四元状态(T 态)的聚合人血红蛋白(PolyhHb)具有很大的前景,可以满足过去聚合 HBOCs 失败的临床需求。这项工作表明,通过两步切向流过滤(TFF)纯化工艺分离 T 态 PolyhHb,使得 Hb 聚合物夹在 500 kDa 和 0.2 μm 之间,从而产生均匀的聚合物尺寸,并在很大程度上消除了在体内引起有害副作用的 Hb 物质。这些材料的生物物理特性表明它们作为 RBC 替代品的潜在有效性,并验证了低分子量 Hb 聚合物和无细胞 Hb 的低百分比。尺寸排阻色谱法证实 T 态 PolyhHb 可以一致地生产在 500 kDa 和 0.2 μm 之间的尺寸范围内。此外,所产生的所有 PolyhHb 物质的平均分子量比商业聚合 HBOCs Hemolink 和 Oxyglobin 分别大一个或两个数量级。结合珠蛋白结合动力学证实,两步 TFF 处理 PolyhHb 可可靠地去除无细胞 Hb 和低分子量聚合 Hb 物质。与未修饰的 Hb 和前几代商业聚合 HBOCs 相比,T 态 PolyhHb 表现出较低的自动氧化速率。这些结果表明 T 态 PolyhHb 作为下一代聚合 HBOC 的可行性,可潜在用于输血医学。